Shattuck Labs, Inc. ((STTK)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shattuck Labs, Inc. is conducting a Phase 1 clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Phase 1 Study of SL-325 in Healthy Volunteers.’ The study aims to evaluate the safety and tolerability of SL-325, a DR3 blocking antibody, in healthy individuals. This research is significant as it represents the first human trial of SL-325, potentially paving the way for future therapeutic applications.
The intervention being tested is SL-325, a biological treatment designed to block DR3, with the goal of assessing its safety profile. Participants in the study receive either single or multiple doses of SL-325 or a placebo.
The study is interventional, with a randomized and sequential design. It employs a double-blind approach, meaning both participants and investigators are unaware of who receives the treatment or placebo. The primary purpose is to evaluate treatment effects.
The study began on August 28, 2025, with recruitment currently ongoing. The primary completion and estimated study completion dates are yet to be announced. The last update was submitted on the same day as the study’s initiation.
This update could influence Shattuck Labs’ stock performance, as positive results may boost investor confidence and interest. The study’s progress is crucial for stakeholders, with potential implications for competitors in the biopharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.